Abstract | OBJECTIVE: METHODS: Patients with Stage IIB-IIIA NSCLC treated with NA-ChRT, completion surgery, and underwent molecular profile testing were identified in a lung cancer database. Pathologic response was quantified using: (i) major pathologic response (MPR), (ii) complete pathologic response (pCR), and (iii) mean residual viable tumor cells ( MRTC). Two groups were formed based on the presence or absence of driver mutations. Clinical and pathological correlations between the groups were studied. RESULTS: Forty-seven patients underwent tumor molecular profile testing, NA-ChRT, and completion surgery. Compared to the no-driver mutation group, the driver mutation group had lower MPR (23% vs 71%, p = 0.003), pCR (0% vs 26%, p = 0.02), and higher MRTC (43.4% vs 15.8%, p = 0.009). Univariate analysis showed an increased MPR rate for smokers, squamous cell histology, ChRT-surgery interval >65 days, and no-driver mutations. Multivariate analysis showed that only no-driver mutations (OR 0.39, p = 0.02) remained significant for MPR. PD-L1 status did not affect MPR. At 2 years, the driver mutation group had lower rates of local control (Hazard ration [HR] 0.67, p = 0.17) and disease-free survival (HR 0.5, p = 0.001). Overall survival was similar for both groups (HR = 1.04, p = 0.86). CONCLUSION: Following 60 Gray NA-ChRT, tumors with a driver mutation had lower MPR and pCR rates than tumors without a driver mutation. PD-L1 was not associated with tumor regression. ADVANCES IN KNOWLEDGE: Patients with resectable LA-NSCLC and an EGFR driver mutation treated with neoadjuvant-ChRT and completion surgery have reduced pathologic regression, lower local control rates, and shorter disease-free survival than patients without a driver mutation. Evaluation of molecular testing should be introduced in LA-NSCLC intended for prognostication and treatment decisions.
|
Authors | Sarit Appel, Jair Bar, Akram Saad, Edith Michelle Marom, Damien Urban, Amir Onn, Hadas Gantz-Sorotsky, Ran Yosef Kremer, Alon Ben-Nun, Marina Perelman, Efrat Ofek, Rinat Yacobi, Sameh Daher, Adi Rasco, Zvi Symon, Yaacov Richard Lawrence, Jeffrey Goldstein |
Journal | The British journal of radiology
(Br J Radiol)
Vol. 96
Issue 1152
Pg. 20220763
(Dec 2023)
ISSN: 1748-880X [Electronic] England |
PMID | 37751214
(Publication Type: Journal Article)
|
Chemical References |
- ErbB Receptors
- EGFR protein, human
|
Topics |
- Humans
- Carcinoma, Non-Small-Cell Lung
(genetics, therapy)
- Lung Neoplasms
(therapy, drug therapy)
- Neoadjuvant Therapy
- ErbB Receptors
(genetics)
- Mutation
|